FDA Drug Safety Podcasts
By U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 12
Reviews: 0
Episodes: 30
Description
FDA Drug Safety Podcasts, produced by FDA's Center for Drug Evaluation and Research, provide emerging safety information about drugs in conjunction with the release of Drug Safety Communications. For more information, please visit: www.fda.gov/drugsafetypodcasts
| Episode | Date |
|---|---|
|
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis
|
Jan 02, 2025 |
|
FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause
|
Sep 20, 2024 |
|
FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab)
|
Feb 06, 2024 |
|
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity
|
Jan 26, 2024 |
|
FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan)
|
Dec 08, 2023 |
|
FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions
|
May 31, 2023 |
|
FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use
|
May 10, 2023 |
|
FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)
|
Dec 16, 2022 |
|
FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)
|
Jul 27, 2022 |
|
FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns
|
Jul 07, 2022 |
|
FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-containing contrast media for medical imaging
|
Apr 13, 2022 |
|
FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)
|
Feb 09, 2022 |
|
FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain
|
Jan 24, 2022 |
|
FDA warns that getting alcohol-based hand sanitizer in the eyes can cause serious injury
|
Nov 09, 2021 |
|
FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions
|
Sep 08, 2021 |
|
FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins
|
Jul 22, 2021 |
|
FDA warns that vapors from alcohol-based hand sanitizers can have side effects
|
Jun 21, 2021 |
|
Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis
|
Jun 03, 2021 |
|
Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease
|
Apr 02, 2021 |
|
FDA warns that abuse and misuse of the OTC nasal decongestant propylhexedrine can lead to serious harm
|
Mar 29, 2021 |
|
Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)
|
Feb 08, 2021 |
|
FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid
|
Oct 22, 2020 |
|
FDA warns about serious problems with high doses of the allergy medicine diphenhydramine (Benadryl)
|
Sep 29, 2020 |
|
FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class
|
Sep 29, 2020 |
|
FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
|
Sep 01, 2020 |
|
FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder
|
Jul 29, 2020 |
|
FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems
|
Apr 24, 2020 |
|
FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market
|
Feb 19, 2020 |
|
FDA strengthens warning that untreated constipation caused by schizophrenia medicine clozapine (Clozaril) can lead to serious bowel problems
|
Feb 10, 2020 |
|
Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin)
|
Jan 23, 2020 |